Stock Events

Stock Events

Adicet Bio 

€6.27
56
+€0.22+3.7% Monday 07:15

Statistics

Day High
0.3788
Day Low
0.3788
52W High
0.972
52W Low
0.3362
Volume
-
Avg. Volume
-
Mkt Cap
961.22M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Oct 18
€0.06
Jun 18
€0.06
Mar 18
€0.37
Dec 17
€0.39
Sep 17
€0.38
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-4.64
-3.19
-1.75
-0.3
Expected EPS
-1.588376
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-222.13MNet Income

Analyst Ratings

34.40Average Price Target
The highest estimate is 68.29.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is focused on the development of programmed cellular immunotherapies for cancer and immune disorders, similar to Adicet Bio's focus on cell therapies for cancer, making them direct competitors in the cell therapy space.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics operates in the field of allogeneic CAR T cell therapies, directly competing with Adicet Bio's allogeneic cell therapy approach for treating cancer.
CRISPR Therapeutics
CRSP
Mkt Cap5.39B
CRISPR Therapeutics is engaged in gene editing and CAR-T therapy developments, competing in the innovative therapy space including cancer treatments, overlapping with Adicet Bio's focus areas.
Novartis
NVS
Mkt Cap304.1B
Novartis is a large pharmaceutical company with a strong presence in the cell therapy market, including Kymriah, a CAR-T therapy for cancer, making it a competitor to Adicet Bio.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR-T therapy for cancer, directly competing with Adicet Bio's cell therapy approaches.
Precigen
PGEN
Mkt Cap2.49B
Precigen is a biotechnology company that develops gene and cell therapies, including CAR-T therapies for cancer, making it a competitor in the same field as Adicet Bio.

About

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Show more...
CEO
Mr. Chen Schor BA, CPA, M.B.A.
Employees
152
Country
United States
ISIN
US0070021086
WKN
000A2QESQ

Listings

STU
DE
1IJ.STU
F
DE
1IJ.F
MU
DE
1IJ.MU
LSE
GB
0HX7.LSE

0 Comments

Share your thoughts

FAQ

What is Adicet Bio stock price today?▼
The current price of 1IJA.F is €6.27 EUR — it has increased by +3.7% in the past 24 hours. Watch Adicet Bio stock price performance more closely on the chart.
What is Adicet Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Adicet Bio stocks are traded under the ticker 1IJA.F.
Is Adicet Bio stock price growing?▼
1IJA.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Adicet Bio has showed a -30.19% decrease.
What is Adicet Bio market cap?▼
Today Adicet Bio has the market capitalization of 961.22M
What is Adicet Bio revenue for the last year?▼
Adicet Bio revenue for the last year amounts to 0 EUR.
What is Adicet Bio net income for the last year?▼
1IJA.F net income for the last year is -222.13M EUR.
Does Adicet Bio pay dividends?▼
Yes, 1IJA.F dividends are paid semi-annual. The last dividend per share was 0.06 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Adicet Bio have?▼
As of September 07, 2026, the company has 152 employees.
In which sector is Adicet Bio located?▼
Adicet Bio operates in the Health & Wellness sector.
When did Adicet Bio complete a stock split?▼
The last stock split for Adicet Bio was on December 30, 2025 with a ratio of 1:16.
Where is Adicet Bio headquartered?▼
Adicet Bio is headquartered in Boston, United States.